VivoSeq
Oncology

Chronic Lymphocytic Leukaemia

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Chronic Lymphocytic Leukaemia is an early-stage landscape with 0 programs across 5 companies. The most active players are Gilead, AstraZeneca, Roche.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalS

Santaris Pharma A/S

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed3 · 38%
Recruiting2 · 25%
Unknown status2 · 25%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT05557695·350 enrolled
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT06812715·40 enrolled
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Completed·Gilead logoGilead·N/A·NCT03582098·112 enrolled
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Completed·Roche logoRoche·N/A·NCT01224093·219 enrolled
SPC2996 in Chronic Lymphocytic Leukaemia
Completed·SSantaris Pharma A/S·Phase 1/2·NCT00285103·46 enrolled
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
Withdrawn·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03343678
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
Unknown status·UUniversity of Liverpool·Phase 3·NCT01678430·670 enrolled
Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia
Unknown status·—·N/A·NCT05145101·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)